Inactief instrument

Andere talen CanaQuest Medical Corp Other OTC

Aandelen

CA01551X1087

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

NHL Alumni Association Partners with CanaQuest and NEEKA Health to Conduct Studies for Anxiety and Quality of Life in Former NHL Players	31-10-23
CanaQuest Medical Corp. cancelled the transaction announced on October 26, 2022	26-10-23
CANAQUEST Announces Award of European Cannabinoid Patent	20-09-23
CanaQuest Medical Corp. Announces Award of European Cannabinoid Patent	19-09-23
CanaQuest Awarded Best Global Medical Cannabinoid Development Company 2023 by UK-based Global Health and Pharma for their 8th Annual Healthcare and Pharmaceutical Program	27-07-23
CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD	08-12-22
CanaQuest Medical Corp. announced a financing transaction	26-10-22
CanaQuest Medical Corp. Launches Mentanine (R) (Cannabidiol + IP Formula) in the US	08-09-22
CanaQuest Medical : Interim Consolidated Consolidated Financial Statements (unaudited) - June 30, 2022	08-08-22
CanaQuest Medical : Attorney Letter	18-07-22
CanaQuest Medical : Financial Statements (unaudited) - March 31, 2022	14-06-22
CanaQuest Medical Corp. Appoints Rob Rinderman as New Director of Communications	07-04-21
Canaquest Signs Medicinal Cannabis Education Partnership with the Canadian Cannabis Dispute Resolution Centre	11-03-21
CANAQUEST MEDICAL CORP Announces New Production and Distribution Agreement with PurCann Pharma and SiliCycle Inc	02-02-21
CANAQUEST MEDICAL CORP SECURES APPROVAL FOR LISTING ON THE OCMX™, AN ONLINE INVESTOR AND FINANCIAL CONNECTION PORTAL	17-09-20
UPDATE: CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL (“CBD”) FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE	14-07-20
CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL (“CBD”) FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE	14-07-20
CanaQuest Medical Corp. Files A Provisional Cannabidiol/Omega-3 Patent, Trade Named Mentanine®	14-07-20
Canaquest Medical Corp Awaits Health Canada Approval for Sales and Export of Mentabinol®	06-02-20
CanaQuest Medical Corp Awaits Health Canada Approval for Sales and Export of Mentabinol®	06-02-20

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen CanaQuest Medical Corp Other OTC

Aandelen

CA01551X1087

Andere talen

Filters